Clinical trials: Autoimmune Disorder
Rheumatoid Arthritis
An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis
This was a multicenter, open-label extension (OLE) Phase II study designed to evaluate the long-term efficacy and safety of ALX-0061 (i.e., vobarilizumab) administered subcutaneously (s.c.) in subjects with active rheumatoid…
- Trial name
- NCT02518620
- Testing
- ALX-0061
- Where
- 57 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 406 people
- Sponsor
- Ablynx, a Sanofi company
Rheumatoid Arthritis, Ankylosing Spondylitis
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
We aim to translate these findings into patients with rheumatoid arthritis and other conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic arthritis and ankylosing spondylitis.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01060098
- Testing
- anti-TNF therapy (etanercept or adalimumab)
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Imperial College London
Diabetes Mellitus, Type 1
Assessment of an Automatic Closed-loop Insulin Delivery System
The overall aim of this research proposal is to determine the safety, feasibility and efficacy of an automatic closed-loop insulin delivery system.
- Trial name
- NCT02366767
- Testing
- Automatic closed-loop insulin delivery, Control
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
Type 1 Diabetes
Role of Exenatide in Type 1 Diabetes
The purpose of this study is to see if giving exenatide and insulin before a meal would lower blood sugars after the meal. This study may help in developing new treatments to help control high blood sugars after meals.
- Trial name
- NCT00456300
- Testing
- Exenatide, Insulin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Montefiore Medical Center
Myelodysplastic Syndromes, Thrombocytopenia
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Background: Myelodysplastic syndromes (MDS) are bone marrow disorders characterized by anemia, neutropenia, and thrombocytopenia (low red blood cell, white blood cell, and platelet counts).
- Trial name
- NCT00961064
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Rheumatoid Arthritis
Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550
All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study.
- Trial name
- NCT01059864
- Testing
- CP-690,550, Atorvastatin
- Where
- 15 sites in United States, South Korea
- Volunteers
- 111 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission
The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab in combination with…
- Trial name
- ADMIRE (NCT00808509)
- Testing
- adalimumab, methotrexate
- Where
- 8 sites in Sweden
- Volunteers
- 33 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Multiple Sclerosis
tDCS and Glucose Uptake in Leg Muscles
This study is to examine the efficacy of tDCS to improving walking in people with Multiple Sclerosis (PwMS). Our study compromises 1 group of subjects with MS which will attend the lab for three sessions.
- Trial name
- NCT04016844
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Iowa
Idiopathic Thrombocytopenic Purpura
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
The purpose of this study is to determine the safety and efficacy of AKR-501 (avatrombopag) administered in participants with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study…
- Trial name
- NCT00625443
- Testing
- Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets)
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Eisai Inc.
Rheumatoid Arthritis
Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).
- Trial name
- NCT01313208
- Testing
- etanercept, DMARD Therapy
- Where
- 47 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Amgen
Relapsing-Remitting Multiple Sclerosis
Natalizumab (Tysabri) Re-Initiation of Dosing
The primary objectives for the initial treatment period of this study are to further evaluate the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions and immunogenicity following re-exposure to…
- Trial name
- STRATA (NCT00297232)
- Testing
- Natalizumab
- Where
- 112 sites in Australia, Belgium and 19 more
- Volunteers
- 1,094 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS)…
- Trial name
- RELIEF (NCT02064816)
- Testing
- Rebif®
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Immune Thrombocytopenic Purpura
A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)
It is known that intravenous immunoglobulins can induce hemolysis, but the mechanism is not known in detail. The primary objective of this study was to investigate the specificity of antigens on red blood cells in patients with…
- Trial name
- NCT01390649
- Testing
- IgPro10
- Where
- 17 sites in Bulgaria, Romania and 1 more
- Volunteers
- 57 people
- Sponsor
- CSL Behring
Systemic Lupus Erythematosus
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- EMBODY2 (NCT01261793)
- Testing
- Epratuzumab
- Where
- 133 sites in United States, Brazil and 14 more
- Volunteers
- 791 people
- Sponsor
- UCB Pharma
Systemic Lupus Erythematosus
A Phase II Study of M2951 in SLE
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus…
- Trial name
- NCT02975336
- Testing
- M2951
- Where
- 157 sites in United States, Argentina and 17 more
- Volunteers
- 469 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Rheumatoid Arthritis
Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label…
- Trial name
- NCT00603993
- Testing
- Adalimumab
- Where
- 16 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
Primary Objective: To demonstrate that sarilumab (SAR153191/REGN88) on top of methotrexate (MTX) was superior in efficacy to placebo for the relief of signs and symptoms of rheumatoid arthritis (RA), in participants with active…
- Trial name
- NCT01217814
- Testing
- Sarilumab, Golimumab, methotrexate (MTX)
- Where
- 14 sites in United States, Colombia and 4 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core…
- Trial name
- NCT01662063
- Testing
- Tocilizumab
- Where
- 79 sites in United States, Puerto Rico
- Volunteers
- 218 people
- Sponsor
- Genentech, Inc.
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 [NCT01519791].
- Trial name
- C-early (NCT01521923)
- Testing
- Certolizumab Pegol + Methotrexate (MTX)
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 359 people
- Sponsor
- UCB Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.